A Study of Molecular Risk Panels in Chinese Breast Cancer Patients

Dr. Margaret Chen is conducting the MammaPrint study looking at genetic biomarkers among Chinese women with early stage breast cancer in the US and Hong Kong, in collaboration with Dr. Ava Kwong.  The trial will focus on the use of MammaPrint, TargetPrint, BluePrint and Research Gene Panel assays. The goal is to identify genes that control the growth and spread of breast cancer in this population.  Assessment of these tumor activities can better identify women whose cancers are less aggressive and less likely to recur, and therefore, can safely forego potentially toxic chemotherapy. Learn more about this trial here.

Download a patient flyer about MammaPrint and BluePrint assays here.  (English | Chinese)